Archiv
Archiv anzeigen:
bis


Anticoagulant Therapy for Immune Thrombocytopenia

David Green, MD, PhD reviewing Balitsky AK et al. Blood 2018 Nov 8

A new risk-assessment tool identified patients who should receive treatment.


Predicting Outcomes in Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Kurtz DM et al. J Clin Oncol 2018 Oct 1

Pretreatment levels of circulating tumor DNA and the rapidity of clearance with therapy were predictive of 2-year responses.


Rethinking Minimally Invasive Surgery for Cervical Cancer

Andrew M. Kaunitz, MD reviewing Ramirez PT et al. N Engl J Med 2018 Oct 31, Fader AN. N Engl J Med 2018 Oct 31, Melamed A et al. N Engl J Med 2018 Oct 31

Two studies raise concerns about laparoscopic and robotic hysterectomy for early-stage disease.


Platelet Transfusion in Preterm Neonates

David Green, MD, PhD reviewing Curley A et al. N Engl J Med 2018 Nov 2

Transfusion at a high-versus-low platelet-count threshold (<50,000/μL or <25,000/μL) was associated with a significantly higher rate of death or major bleeding.


Triplet Therapy for Multiple Myeloma

Michael E. Williams, MD, ScM reviewing Dimopoulos MA et al. N Engl J Med 2018 Nov 8

Combining the monoclonal antibody elotuzumab with pomalidomide and dexamethasone improved outcomes in relapsed or refractory patients.


The Disease Spectrum of Sickle Cell Trait

David Green, MD, PhD reviewing Naik RP et al. Ann Intern Med 2018 Oct 30

Risks were found to be increased for renal outcomes, venous thromboembolism, and exertion-related injury, but not for hypertension, myocardial infarction, or heart failure.


A New Approach to Lymphoma Treatment

Michael E. Williams, MD, ScM reviewing Advani R et al. N Engl J Med 2018 Nov 1, Mantovani A and Longo DL. N Engl J Med 2018 Nov 1

Combining rituximab with an anti-CD47 monoclonal antibody led to high response rates in relapsed or refractory B-cell lymphoma.


Molecular Classification of Myeloproliferative Disorders

Michael E. Williams, MD, ScM reviewing Grinfeld J et al. N Engl J Med 2018 Oct 11

Genomic analysis correlates with clinical features and characterizes prognosis.


Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Archiv
Seite von 76
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen
Kantonsspital St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Im «New England Journal of Medicine» sind wieder einige interessante, auch «practice changing» Publikationen erschienen.

Kommentar weiterlesen

Apalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Smith MR et al. N Engl J Med 2018 Feb 8

Metastasis-free survival was significantly longer with apalutamide than with placebo.


Second-Line Olaparib for Gastric Cancer

David H. Ilson, MD, PhD reviewing Bang Y-J et al. Lancet Oncol 2017 Dec

Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.


Predicting Response to Immunotherapy in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Rizvi H et al. J Clin Oncol 2018 Jan 16

Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.


Prolonged Adjuvant Aromatase Inhibitor Treatment for Early Breast Cancer

William J. Gradishar, MD reviewing Blok EJ et al. J Natl Cancer Inst 2018 Jan 1, Goldvaser H et al. J Natl Cancer Inst 2018 Jan 1, Pohlmann PR and Isaacs C. J Natl Cancer Inst 2018 Jan 1

Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.


Prognosis of Monoclonal Gammopathy of Undetermined Significance

David Green, MD, PhD reviewing Kyle RA et al. N Engl J Med 2018 Jan 18

Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.


Prognosis for BRCA-Mutated Breast Cancer

William J. Gradishar, MD reviewing Copson ER et al. Lancet Oncol 2018 Jan 11

Survival is similar between BRCA mutation carriers versus those with sporadic disease.


Electrical Field Therapy for Glioblastoma

Roy E. Strowd, MD reviewing Stupp R et al. JAMA 2017 Dec 19

Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.


Atezolizumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Powles T et al. Lancet 2017 Dec 18, Massari F and Di Nunno V. Lancet 2017 Dec 18

Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.


Pembrolizumab for Cisplatin-Ineligible Patients with Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Balar AV et al. Lancet Oncol 2017 Sep 26

First-line therapy demonstrated antitumor activity in a phase II study.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.